Download the 800 million pill the truth behind the cost of new drugs in pdf or read the 800 million pill the truth behind the cost of new drugs in pdf online books in PDF, EPUB and Mobi Format. Click Download or Read Online button to get the 800 million pill the truth behind the cost of new drugs in pdf book now. This site is like a library, Use search box in the widget to get ebook that you want.

The 800 Million Pill

Author: Merrill Goozner
Publisher: Univ of California Press
ISBN: 9780520246706
Size: 39.73 MB
Format: PDF, Mobi
View: 4988
Download and Read
Demonstrates that important new drugs are the results of innovative work done at taxpayer-funded universities and at the National Institutes of Health, rather than by pharmaceutical firms who reap the profit and drive up the cost of prescription drugs.

Big Pharma

Author: Mikkel Borch-Jacobsen
Publisher: Piper ebooks
ISBN: 3492969291
Size: 42.83 MB
Format: PDF
View: 2771
Download and Read
Die Medizin will uns Menschen gesund erhalten und Krankheiten heilen? Das Gegenteil ist der Fall: Das von der Pharmaindustrie beherrschte Gesundheitswesen verfolgt rein ihre Profitinteressen und setzt dabei die Gesundheit der Verbraucher aufs Spiel. Mikkel Borch-Jakobsen hat in diesem Buch zwölf hochkarätige internationale Autoren zusammengebracht, die sich jeder als „Whistleblower“ einen Namen gemacht haben: Wissenschaftler, Pharma-Spezialisten und Journalisten. Sie zeigen u.a., wie psychische Erkrankungen zu einem riesigen Geschäftsfeld gemacht und Grenzwerte von Cholesterin manipuliert werden, Alltagsstress pathologisiert und Werbung für Medikamente als neutrale Information getarnt wird. Ein beunruhigendes und brisantes Aufdeckerbuch, das zeigt, was alles getan wird, um mehr Medikamente zu verkaufen – für die Gewinnmaximierung der Pharmaindustrie, und zum Schaden von uns allen.

Parallelimporte Und Der Pharmamarkt

Author: Guido Barsuglia
Publisher: Peter Lang
ISBN: 9783039112326
Size: 51.50 MB
Format: PDF
View: 7280
Download and Read
Aus der Sicht der Konsumenten sind Preise fur Guter und Dienstleistungen immer zu hoch. Aus der Sicht der Produzenten sind sie immer zu tief. Der Wettbewerb sorgt in der Regel dafur, dass keine der beiden Seiten ihr unterschiedliches Preisinteresse ubermachtig durchsetzen kann und die Gesamtwohlfahrt maximiert wird. Doch was passiert, wenn Wettbewerb staatlich eingeschrankt wird? Was passiert mit der Gesamtwohlfahrt, wenn einem Produzenten in verschiedenen Landern eine Monopolstellung verliehen wird (Patent) und sich diese Lander zudem strikt voneinander abschotten (Parallelimportverbot)? Welche Rolle spielen hierbei nationale Hochstpreisregulierungen? Diesen Fragen wird in diesem Buch nachgegangen. Im Zentrum steht dabei ein typischer patentgeschutzter Markt, der Pharmamarkt. Die mehrstufige Analyse zeigt, dass ein Aufheben des Parallelimportverbots zwar wohlfahrtssteigernd sein kann, jedoch weder zur effizientesten noch zur zweiteffizientesten Losung fuhrt. Daruber hinaus werden in diesem Buch juristische und okonomische Parallelimportgrundlagen erarbeitet und ein simpler Implementierungsweg fur Ramsey Preise auf einem globalen Pharmamarkt vorgestellt."

Deadly Monopolies

Author: Harriet A. Washington
Publisher: Anchor
ISBN: 0385534051
Size: 69.66 MB
Format: PDF, ePub, Mobi
View: 317
Download and Read
From the award-winning author of Medical Apartheid, an exposé of the rush to own and exploit the raw materials of life—including yours. Think your body is your own to control and dispose of as you wish? Think again. The United States Patent Office has granted at least 40,000 patents on genes controlling the most basic processes of human life, and more are pending. If you undergo surgery in many hospitals you must sign away ownership rights to your excised tissues, even if they turn out to have medical and fiscal value. Life itself is rapidly becoming a wholly owned subsidiary of the medical- industrial complex. Deadly Monopolies is a powerful, disturbing, and deeply researched book that illuminates this “life patent” gold rush and its harmful, and even lethal, consequences for public health. It examines the shaky legal, ethical, and social bases for Big Pharma’s argument that such patents are necessary to protect their investments in new drugs and treatments, arguing that they instead stifle the research, competition, and innovation that can drive down costs and save lives. In opposing the commodification of the body, Harriet Washington provides a crucial human dimension to an often all-too-abstract debate. Like the bestseller The Immortal Life of Henrietta Lacks, Deadly Monopolies reveals in shocking detail just how far the profit motive has encroached in colonizing human life and compromising medical ethics. It is sure to stir debate—and instigate change. From the Hardcover edition.

The Risks Of Prescription Drugs

Author: Donald W. Light
Publisher: Columbia University Press
ISBN: 0231519265
Size: 33.53 MB
Format: PDF, Docs
View: 1499
Download and Read
Few people realize that prescription drugs have become a leading cause of death, disease, and disability. Adverse reactions to widely used drugs, such as psychotropics and birth control pills, as well as biologicals, result in FDA warnings against adverse reactions. The Risks of Prescription Drugs describes how most drugs approved by the FDA are under-tested for adverse drug reactions, yet offer few new benefits. Drugs cause more than 2.2 million hospitalizations and 110,000 hospital-based deaths a year. Serious drug reactions at home or in nursing homes would significantly raise the total. Women, older people, and people with disabilities are least used in clinical trials and most affected. Health policy experts Donald Light, Howard Brody, Peter Conrad, Allan Horwitz, and Cheryl Stults describe how current regulations reward drug companies to expand clinical risks and create new diseases so millions of patients are exposed to unnecessary risks, especially women and the elderly. They reward developing marginally better drugs rather than discovering breakthrough, life-saving drugs. The Risks of Prescription Drugs tackles critical questions about the pharmaceutical industry and the privatization of risk. To what extent does the FDA protect the public from serious side effects and disasters? What is the effect of giving the private sector and markets a greater role and reducing public oversight? This volume considers whether current rules and incentives put patients' health at greater risk, the effect of the expansion of disease categories, the industry's justification of high U.S. prices, and the underlying shifts in the burden of risk borne by individuals in the world of pharmaceuticals. Chapters cover risks of statins for high cholesterol, SSRI drugs for depression and anxiety, and hormone replacement therapy for menopause. A final chapter outlines six changes to make drugs safer and more effective. Suitable for courses on health and aging, gender, disability, and minority studies, this book identifies the Risk Proliferation Syndrome that maximizes the number of people exposed to these risks. Additional Columbia / SSRC books on the privatization of risk and its implications for Americans: Bailouts: Public Money, Private ProfitEdited by Robert E. Wright Disaster and the Politics of InterventionEdited by Andrew Lakoff Health at Risk: America's Ailing Health System-and How to Heal ItEdited by Jacob S. Hacker Laid Off, Laid Low: Political and Economic Consequences of Employment InsecurityEdited by Katherine S. Newman Pensions, Social Security, and the Privatization of RiskEdited by Mitchell A. Orenstein

Race In A Bottle

Author: Jonathan Kahn
Publisher: Columbia University Press
ISBN: 0231531273
Size: 28.21 MB
Format: PDF, ePub
View: 210
Download and Read
At a ceremony announcing the completion of the first draft of the human genome in 2000, President Bill Clinton declared, "I believe one of the great truths to emerge from this triumphant expedition inside the human genome is that in genetic terms, all human beings, regardless of race, are more than 99.9 percent the same." Yet despite this declaration of unity, biomedical research has focused increasingly on mapping that.1 percent of difference, particularly as it relates to race. This trend is exemplified by the drug BiDil. Approved by the FDA in 2005 as the first drug with a race-specific indication on its label, BiDil was originally touted as a pathbreaking therapy to treat heart failure in black patients and help underserved populations. Upon closer examination, however, Jonathan Kahn reveals a far more complex story. At the most basic level, BiDil became racial through legal maneuvering and commercial pressure as much as through medical understandings of how the drug worked. Using BiDil as a central case study, Kahn broadly examines the legal and commercial imperatives driving the expanding role of race in biomedicine, even as scientific advances in genomics could render the issue irrelevant. He surveys the distinct politics informing the use of race in medicine and the very real health disparities caused by racism and social injustice that are now being cast as a mere function of genetic difference. Calling for a more reasoned approach to using race in biomedical research and practice, Kahn asks readers to recognize that, just as genetics is a complex field requiring sensitivity and expertise, so too is race, particularly in the field of biomedicine.

Pills Power And Policy

Author: Dominique Tobbell
Publisher: Univ of California Press
ISBN: 0520952421
Size: 59.16 MB
Format: PDF, ePub, Docs
View: 7404
Download and Read
Since the 1950s, the American pharmaceutical industry has been heavily criticized for its profit levels, the high cost of prescription drugs, drug safety problems, and more, yet it has, together with the medical profession, staunchly and successfully opposed regulation.Pills, Power, and Policyoffers a lucid history of how the American drug industry and key sectors of the medical profession came to be allies against pharmaceutical reform. It details the political strategies they have used to influence public opinion, shape legislative reform, and define the regulatory environment of prescription drugs. Untangling the complex relationships between drug companies, physicians, and academic researchers, the book provides essential historical context for understanding how corporate interests came to dominate American health care policy after World War II.

Disaster And The Politics Of Intervention

Author: Andrew Lakoff
Publisher: Columbia University Press
ISBN: 0231519257
Size: 16.45 MB
Format: PDF, ePub, Mobi
View: 2134
Download and Read
Government plays a critical role in mitigating individual and collective vulnerability to disaster. Through measures such as disaster relief, infrastructure development, and environmental regulation, public policy is central to making societies more resilient. However, the recent drive to replace public institutions with market mechanisms has challenged governmental efforts to manage collective risk. The contributors to this volume analyze the respective roles of the public and private sectors in the management of catastrophic risk, addressing questions such as: How should homeland security officials evaluate the risk posed by terrorist attacks and natural disasters? Are market-based interventions likely to mitigate our vulnerability to the effects of climate change? What is the appropriate relationship between non-governmental organizations and private security firms in responding to humanitarian emergencies? And how can philanthropic efforts to combat the AIDS crisis ensure ongoing access to life-saving drugs in the developing world? More generally, these essays point to the way thoughtful policy intervention can improve our capacity to withstand catastrophic events. Additional Columbia / SSRC books on the Privatization of Risk and its Implications for Americans Bailouts: Public Money, Private ProfitEdited by Robert E. Wright Health at Risk: America's Ailing Health System-and How to Heal ItEdited by Jacob S. Hacker Laid Off, Laid Low: Political and Economic Consequences of Employment InsecurityEdited by Katherine S. Newman Pensions, Social Security, and the Privatization of RiskEdited by Mitchell A. Orenstein

Financialization And Strategy

Author: Julie Froud
Publisher: Routledge
ISBN: 113431454X
Size: 27.73 MB
Format: PDF, ePub, Docs
View: 6372
Download and Read
Considering the recent impact of the capital market on corporate strategy, this text analyzes, through argument and supportive case studies, how pressures from the capital bull market of the 1990s and bear market of the early 2000s, have reshaped management action and calculation in large, publicly quoted US and UK corporations. Beginning with the dissatisfaction with classical strategy and its limited engagement with the processes of financialization, the book moves on to cover three detailed company case studies (General Electric, Ford and GlaxoSmithKline) which use long run financial data and analysis of company and industry narratives to illustrate and explore key themes. The book emphasizes the importance of company and industry narrative, while also analyzing long term financial results, and helps to explain the limits of management action and the burden of expectations placed on corporate governance. Presenting financial and market information on trajectory in an accessible way, this book provides a distinctive, critical social science account of management in large UK and US corporations, and it is a valuable resource for students, scholars and researchers of business, management, political economy and non-mainstream economics. short listed for the 2007 IPEG Book Prize

The Business Of Healthcare Innovation

Author: Lawton R. Burns
Publisher: Cambridge University Press
ISBN: 9780521838986
Size: 42.71 MB
Format: PDF, ePub, Docs
View: 4071
Download and Read
The first wide-ranging analysis of business trends in the manufacturing segment of the health care industry.